1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Eight More Years: US Supreme Court Sinks Sandoz’ Hopes On Enbrel

Erelzi Biosimilar Etanercept Is Now Barred Until 2029 In The US

 
• By Dave Wallace

Sandoz’ arguments urging the US Supreme Court to review patent litigation around Amgen’s Enbrel have fallen on deaf ears, blocking a route to market for biosimilar etanercept until 2029 in the US.

Road Sign 2029
The decision blocks US etanercept biosimilars until 2029 • Source: Alamy

Sandoz has failed in its attempt to convince the US Supreme Court to review patent litigation with Amgen over its Enbrel (etanercept) biologic brand, blocking biosimilars from the market for a further eight years, until 2029.

Earlier this year, Sandoz had confirmed that it would be trying one last time to topple patents protecting Enbrel for a further eight years, filing a petition with the Supreme Court for certiorari review of an unfavorable appeals court decision that upheld the validity of two patents shielding the $5bn autoimmune diseases treatment

More from Biosimilars

More from Products

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.